Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989

G. J. Cuchural, D. R. Snydman, L. McDermott, P. B. Iannini, G. B. Hill, Timothy Cleary, J. P. O'Keefe, C. L. Pierson, J. D. Rihs, S. M. Finegold

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.

Original languageEnglish
Pages (from-to)122-136
Number of pages15
JournalClinical Therapeutics
Volume14
Issue number1
StatePublished - Apr 22 1992
Externally publishedYes

Fingerprint

Cefotetan
Ceftizoxime
Sulbactam
Cefoxitin
Bacteroides fragilis
Clavulanic Acid
Clindamycin
Ceftriaxone
Imipenem
R Factors
Metronidazole
Chloramphenicol
beta-Lactamases
Pharmaceutical Preparations
beta-Lactamase Inhibitors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cuchural, G. J., Snydman, D. R., McDermott, L., Iannini, P. B., Hill, G. B., Cleary, T., ... Finegold, S. M. (1992). Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. Clinical Therapeutics, 14(1), 122-136.

Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. / Cuchural, G. J.; Snydman, D. R.; McDermott, L.; Iannini, P. B.; Hill, G. B.; Cleary, Timothy; O'Keefe, J. P.; Pierson, C. L.; Rihs, J. D.; Finegold, S. M.

In: Clinical Therapeutics, Vol. 14, No. 1, 22.04.1992, p. 122-136.

Research output: Contribution to journalArticle

Cuchural, GJ, Snydman, DR, McDermott, L, Iannini, PB, Hill, GB, Cleary, T, O'Keefe, JP, Pierson, CL, Rihs, JD & Finegold, SM 1992, 'Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989', Clinical Therapeutics, vol. 14, no. 1, pp. 122-136.
Cuchural GJ, Snydman DR, McDermott L, Iannini PB, Hill GB, Cleary T et al. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. Clinical Therapeutics. 1992 Apr 22;14(1):122-136.
Cuchural, G. J. ; Snydman, D. R. ; McDermott, L. ; Iannini, P. B. ; Hill, G. B. ; Cleary, Timothy ; O'Keefe, J. P. ; Pierson, C. L. ; Rihs, J. D. ; Finegold, S. M. / Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. In: Clinical Therapeutics. 1992 ; Vol. 14, No. 1. pp. 122-136.
@article{3e7d4fdec3874ff5938dc726a8e8a9e3,
title = "Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989",
abstract = "A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1{\%} at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4{\%}, 25{\%}, 26{\%}, and 46{\%}, respectively. Clindamycin resistance was 10{\%} at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.",
author = "Cuchural, {G. J.} and Snydman, {D. R.} and L. McDermott and Iannini, {P. B.} and Hill, {G. B.} and Timothy Cleary and O'Keefe, {J. P.} and Pierson, {C. L.} and Rihs, {J. D.} and Finegold, {S. M.}",
year = "1992",
month = "4",
day = "22",
language = "English",
volume = "14",
pages = "122--136",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989

AU - Cuchural, G. J.

AU - Snydman, D. R.

AU - McDermott, L.

AU - Iannini, P. B.

AU - Hill, G. B.

AU - Cleary, Timothy

AU - O'Keefe, J. P.

AU - Pierson, C. L.

AU - Rihs, J. D.

AU - Finegold, S. M.

PY - 1992/4/22

Y1 - 1992/4/22

N2 - A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.

AB - A national survey of Bacteroides fragilis group was continued in 1989 for the ninth consecutive year. Seven hundred thirty-nine isolates of B fragilis group from eight centers were tested for susceptibility to 14 antimicrobials. Sulbactam and clavulanic acid, beta-lactamase inhibitors, were tested at a constant concentration of 8 μg/ml and 2 μg/ml, respectively. Sulbactam was also tested in a fixed ratio of 1:2. Imipenem, ampicillin + sulbactam, and ticarcillin + clavulanic acid had resistance of < 1% at breakpoints of 8 μg/ml, 16 μg/ml, and 64 μg/ml, respectively. At 32 μg/ml, resistance to cefoxitin, cefotetan, ceftizoxime, and ceftriaxone were 4%, 25%, 26%, and 46%, respectively. Clindamycin resistance was 10% at a breakpoint of 4 μg/ml. No isolates were resistant to chloramphenicol or metronidazole. Resistance for five B fragilis species to cefoxitin, ceftizoxime, and cefotetan varied greatly among both species and participating institutions. The addition of a beta-lactamase inhibitor increased the potency of the betalactam drugs tested as combinations. This finding suggests that beta-lactamase production is the major resistance factor in members of the B fragilis group.

UR - http://www.scopus.com/inward/record.url?scp=0026549348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026549348&partnerID=8YFLogxK

M3 - Article

C2 - 1576621

AN - SCOPUS:0026549348

VL - 14

SP - 122

EP - 136

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -